The risk is higher when immunotherapy comes within 3 months of cranial radiotherapy. The study was published as a preprint and has not yet been peer reviewed.
Remission at 6 months was recorded in 73.1% of rituximab-treated patients and 40.1% of cyclophosphamide-treated patients in a multicenter target trial emulation.